Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX as an Aid to Smoking Cessation.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2012
Price :
$35
*
At a glance
- Drugs Nicotine abuse vaccine (Primary)
- Indications Smoking withdrawal
- Focus Pharmacodynamics
- 11 May 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 11 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Mar 2011 New trial record